Amyloid Plaque News and Research

RSS

Hypometabolism in brain regions of cognitively normal patients associated with Alzheimer's disease

Alzheimer's disease has been linked in many studies to amyloid plaque buildup in the brain, but new research is finding a common thread between amyloid burden and lower energy levels, or metabolism, of neurons in certain areas of the brain associated with Alzheimer's disease-even for people with no sign of cognitive decline.

12 Jun 2013

Scientists reexamine gene strongly linked to Alzheimer's disease

Scientists' picture of how a gene strongly linked to Alzheimer's disease harms the brain may have to be revised, researchers at Washington University School of Medicine in St. Louis have found. People with harmful forms of the APOE gene have up to 12 times the risk of developing Alzheimer's disease compared with those who have other variations of the gene.

8 May 2013

Studies, search for genetic risk factors needed to predict individual's risk for traumatic brain injury

One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.

6 Apr 2013

Navidea commences enrollment in NAV4694 Phase 2b study to detect erebral β-amyloid plaque

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.

28 Mar 2013

Researchers reprogramming skin cells into brain cells to understand Alzheimer's disease

Sam Gandy, MD, PhD, of the Icahn School of Medicine at Mount Sinai is leading an international team of researchers working to reprogram skin cells into brain cells to gain a better understanding of Alzheimer's disease.

28 Mar 2013

Controlling hypertension earlier in life may limit brain changes associated with Alzheimer's disease

A study in the JAMA Neurology (formerly the Archives of Neurology) suggests that controlling or preventing risk factors such as hypertension earlier in life may limit or delay the brain changes associated with Alzheimer's disease and other age-related neurological deterioration.

19 Mar 2013

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

From Luminex 15 Mar 2013

Amyloid plaques take about 15 years to build up and then plateau: Study

Researchers have identified a possible treatment window of several years for plaques in the brain that are thought to cause memory loss in diseases such as Alzheimer's. The Mayo Clinic study is published in the Feb. 27 online issue of Neurology, the medical journal of the American Academy of Neurology.

28 Feb 2013

BCHE gene variant predicts extent of plaque deposits in Alzheimer's

A study combining genetic data with brain imaging, designed to identify genes associated with the amyloid plaque deposits found in Alzheimer's disease patients, has not only identified the APOE gene -- long associated with development of Alzheimer's -- but has uncovered an association with a second gene, called BCHE.

21 Feb 2013

Activated astrocytes could play a harmful role in Alzheimer's disease

A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease.

12 Dec 2012

Combination of imaging and biomarker tests helps predict Alzheimer's in patients with MCI

Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer's in patients with mild cognitive impairment, according to researchers at Duke Medicine.

11 Dec 2012

Merck commences MK-8931 Phase II/III trial in Alzheimer's

Merck, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.

3 Dec 2012

Studies shake up Alzheimer’s hypotheses

Two studies in people at genetic risk for Alzheimer’s disease reveal very early changes in brain structure and function that may actually precede amyloid beta deposition.

6 Nov 2012

Researchers analyse hydrogen bonds in tiny fibrils of amyloid-beta peptide

Using solid-state nuclear magnetic resonance (NMR) spectroscopy, researchers at Luleå University of Technology in collaboration with Warwick University in the UK for the first time in the world managed to analyse hydrogen bonds in tiny fibrils of Amyloid-beta peptide , which probably causes Alzheimer's disease.

5 Nov 2012

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.

30 Oct 2012

Dementia: A National Crisis – a review of the Manchester 2012 conference

It was clear from the title – Dementia: A National Crisis – that the conference would focus on the important challenges facing many people living with dementia in the country today.

24 Oct 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.

21 Aug 2012

Protein folding: Nobel laureate Ahmed H. Zewail summarizes his insights

Living subjects are very complex systems and, at the same time, stunningly robust and accommodative. The secret of success are their proteins which build up the cells of the organisms, act as cleaners, messengers, transporter, motors, and fulfill much more jobs. How proteins are genetically coded and how their linear chains of amino acids are put together, is in principle well known.

14 Aug 2012

Advanced Radiology to offer Amyvid for detection of AD

Advanced Radiology, a division of RadNet, Inc., a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 237 fully-owned and operated outpatient imaging centers, announced it will be one of a small number of imaging centers in the U.S. to offer Amyvid, a radioactive tracer used in positron emission tomography – computed tomography (PET/CT) imaging that helps to detect the quantity of beta-amyloid plaque in patient's brains.

8 Aug 2012